| 9.56 0.11 (1.16%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 11.84  |
1-year : | 12.89 |
| Resists | First : | 10.14 |
Second : | 11.03 |
| Pivot price | 9.4 |
|||
| Supports | First : | 8.68 | Second : | 7.23 |
| MAs | MA(5) : | 9.41 |
MA(20) : | 9.62 |
| MA(100) : | 8.9 |
MA(250) : | 10.18 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 58.8 |
D(3) : | 48.6 |
| RSI | RSI(14): 47 |
|||
| 52-week | High : | 17.29 | Low : | 6.28 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ TLX ] has closed below upper band by 31.7%. Bollinger Bands are 47.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 9.6 - 9.63 | 9.63 - 9.66 |
| Low: | 9.32 - 9.37 | 9.37 - 9.41 |
| Close: | 9.49 - 9.55 | 9.55 - 9.61 |
Telix Pharmaceuticals Limited (TLX) is a commercial-stage biopharmaceutical entity specializing in the creation and distribution of advanced radiopharmaceuticals. Its core mission is to develop both diagnostic agents and therapeutic treatments for cancer and rare diseases across key international markets, including Australia, Belgium, Japan, Switzerland, and the United States. Among its currently available products, Telix offers Illuccix, designed for the management of prostate cancer, and TLX66-CDx, which serves as an imaging agent for osteomyelitis. The company also maintains a robust pipeline of investigational candidates aimed at various conditions: Prostate Cancer: TLX591, a radio antibody-drug conjugate, and TLX592, a candidate for targeted alpha therapy. Renal (Kidney) Cancer: TLX250-CDx, intended for both diagnosis and treatment, and TLX250, specifically for clear cell renal cell carcinoma. Brain Cancer: This includes TLX101-CDx and TLX101, which targets glioblastoma. Bone Marrow Conditioning: TLX66-CDx and TLX66 are being explored. Soft Tissue Sarcoma: TLX300-CDx and TLX300 are under development for diagnosis and treatment. Founded in 2015, Telix Pharmaceuticals Limited is based in North Melbourne, Australia.
Mon, 15 Jun 2026
Telix Pharmaceuticals ASX TLX 2026: Radiopharma Growth Surge - Kalkine Media
Wed, 03 Jun 2026
Telix Pharmaceuticals Limited (TLX) Presents at 46th Annual William Blair Growth Stock Conference - Slideshow - Seeking Alpha
Wed, 27 May 2026
Telix CEO lines up back-to-back investor talks in Chicago and New York - Stock Titan
Thu, 21 May 2026
Telix Pharmaceuticals (TLX) furnishes AGM addresses, presentation and results via Form 6-K - Stock Titan
Mon, 18 May 2026
Telix Pharmaceuticals Limited (TLX) Stock Analysis: Exploring a Promising 103% Upside Potential - DirectorsTalk Interviews
Tue, 28 Apr 2026
Telix Pharmaceuticals (TLX): How Are Its Clinical Programs Doing? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 339 (M) |
| Shares Float | 273 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0.8 (%) |
| Shares Short | 251 (K) |
| Shares Short P.Month | 270 (K) |
| EPS | -0.02 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.23 |
| Profit Margin | -0.9 % |
| Operating Margin | 1.9 % |
| Return on Assets (ttm) | 1.1 % |
| Return on Equity (ttm) | -1.9 % |
| Qtrly Rev. Growth | 49.2 % |
| Gross Profit (p.s.) | 1.12 |
| Sales Per Share | 2.37 |
| EBITDA (p.s.) | 0.09 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -17 (M) |
| Levered Free Cash Flow | -37 (M) |
| PE Ratio | -478.01 |
| PEG Ratio | 0 |
| Price to Book value | 7.77 |
| Price to Sales | 4.02 |
| Price to Cash Flow | -187.32 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|